In summary, we speculated that PTGS2 (the crucial target of the active compounds of SQP) and JUN (the essential gene among the eight target genes of SQP) are the hub genes for the treatment of NASH. Here, PTGS2 is linked to metabolic dysfunction-associated steatohepatitis.